ZYME

Zymeworks Inc.

A Vancouver-based biopharmaceutical company that engineers antibody-based cancer therapies. Its Azymetric platform builds bispecific antibodies that can latch onto two targets at once, while its ZymeLink technology attaches chemotherapy drugs to antibodies to deliver them straight to tumors. Founded in 2003, the company's lead drug, zanidatamab, targets HER2-positive cancers.